全文获取类型
收费全文 | 980篇 |
免费 | 40篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 28篇 |
妇产科学 | 8篇 |
基础医学 | 132篇 |
口腔科学 | 52篇 |
临床医学 | 74篇 |
内科学 | 203篇 |
皮肤病学 | 23篇 |
神经病学 | 41篇 |
特种医学 | 21篇 |
外科学 | 126篇 |
综合类 | 3篇 |
预防医学 | 98篇 |
眼科学 | 40篇 |
药学 | 90篇 |
中国医学 | 6篇 |
肿瘤学 | 76篇 |
出版年
2023年 | 9篇 |
2022年 | 15篇 |
2021年 | 25篇 |
2020年 | 23篇 |
2019年 | 22篇 |
2018年 | 21篇 |
2017年 | 29篇 |
2016年 | 24篇 |
2015年 | 25篇 |
2014年 | 36篇 |
2013年 | 50篇 |
2012年 | 81篇 |
2011年 | 78篇 |
2010年 | 45篇 |
2009年 | 45篇 |
2008年 | 65篇 |
2007年 | 64篇 |
2006年 | 63篇 |
2005年 | 55篇 |
2004年 | 73篇 |
2003年 | 57篇 |
2002年 | 35篇 |
2001年 | 6篇 |
2000年 | 13篇 |
1999年 | 17篇 |
1998年 | 8篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 3篇 |
1968年 | 1篇 |
排序方式: 共有1024条查询结果,搜索用时 0 毫秒
1.
Background
Due to marginalization, trafficking violence, conflicts with the police and organic and social psychological problems associated with the drug, crack is one of the most devastating drugs currently in use. However, there is evidence that some users manage to stay alive and active while using crack cocaine for many years, despite the numerous adversities and risks involved with this behavior. In this context, the aim of the present study was to identify the strategies and tactics developed by crack users to deal with the risks associated with the culture of use by examining the survival strategies employed by long-term users. 相似文献2.
Prevalence of enterotoxigenic Escherichia coli strains harboring the longus pilus gene in Brazil 总被引:1,自引:0,他引:1 下载免费PDF全文
The longus type IV pilus gene (lngA) was highly prevalent (32.8%) among Brazilian enterotoxigenic Escherichia coli strains producing both heat-labile and heat-stable enterotoxins and bearing the CFA/I, CS1CS3, or CS6 antigen. Furthermore, lngA was more often found in strains isolated from children with diarrhea than in strains isolated from children without diarrhea. 相似文献
3.
An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. 总被引:6,自引:0,他引:6
Cynthia Sung Bernardetta Nardelli David W LaFleur Erich Blatter Marta Corcoran Henrik S Olsen Charles E Birse Oxana K Pickeral Junli Zhang Devanshi Shah Gordon Moody Solange Gentz Lisa Beebe Paul A Moore 《Journal of interferon & cytokine research》2003,23(1):25-36
The long half-life and stability of human serum albumin (HSA) make it an attractive candidate for fusion to short-lived therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc., Rockville, MD) beta is a novel recombinant protein derived from a gene fusion of interferon-beta (IFN-beta ) and HSA. In vitro, Albuferon beta displays antiviral and antiproliferative activities and triggers the IFN-stimulated response element (ISRE) signal transduction pathway. Array analysis of 5694 independent genes in Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the expression of an identical set of 30 genes, including 9 previously not identified. In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c., Albuferon beta demonstrated favorable pharmacokinetic properties. Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum albumin suggest a clinical opportunity for improved IFN-beta therapy. 相似文献
4.
Amadio Eliane Martins Marcos Rodrigo Labat Serra Andrey Jorge dos Santos Solange Almeida Caires Jheniphe Rocha Fernandes Guilherme Henrique Cardosos Leal-Junior Ernesto Cesar Ferrari João Carlos Correa de Tarso Camillo de Carvalho Paulo 《Lasers in medical science》2021,36(7):1427-1435
Lasers in Medical Science - Photobiomodulation therapy (PBMT) has been indicated for enforcement on healing skin wounds. This study evaluated the effects of PBMT on the healing of skin wounds... 相似文献
5.
Gladys Morales Samuel Durán-Agüero Solange Parra-Soto Leslie Landaeta-Díaz Valeria Carpio Brian Cavagnari Israel Rios-Castillo Edna Nava-González Jhon Bejarano-Roncancio Beatriz Núñez-Martínez Karla Cordón-Arrivillaga Eliana Meza-Miranda Saby Mauricio-Alza Georgina Gómez Gabriela Murillo Jacqueline Araneda-Flores 《American journal of human biology》2023,35(8):e23900
6.
Jean-Christophe Zech Laurette Morlé Pascale Vincent Nicole Alloisio Muriel Bozon Colette Gonnet Solange Milazzo Jean-Daniel Grange Christiane Trepsat Jacqueline Godet Henri Plauchu 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》1999,237(5):387-393
· Background: It has been previously described that Wagner disease is linked to chromosome 5q13-q14. This study was carried
out to describe the ophthalmological aspects and report the results of genetic linkage analysis in a large pedigree affected
by Wagner disease. · Methods: Fourty members of one same family agreed to be examined. · Results: Twenty patients presented
vitreoretinal degeneration in both eyes without any extra-ocular abnormalities. In young patients, visual acuity was usually
normal after correction of frequent mild myopia. Presenile cataracts progressed by the third decade and required removal for
visual rehabilitation. The primary disorder involved an abnormal vitreous. A few avascular vitreous bands were usually the
only optical feature in the mostly empty vitreous cavity. A circumferential vitreous condensation formed in contact with the
retina on many spots. Less common retinal findings included retinal detachment, abnormal retinal pigmentation, progressive
atrophy of the RPE simulating choroideremia and lattice degeneration. Genetic analysis revealed a highly significant linkage
(lod score >5.0) between the disease and 10 markers of the chromosome 5q13-q14 region. Two recombination events allowed us
to refine the linked interval to 20 cM between the D5S650 and D5S618 markers. · Conclusion: Ophthalmological aspects of Wagner’s
disease appear to progress with age. Regular ophthalmological examination is important for detecting retinal abnormalities.
The gene involved in Wagner’s disease lies in a 20 cM interval on chromosome 5q13-q14.
Received: 30 June 1998 Revised version received: 5 October 1998 Accepted: 6 October 1998 相似文献
7.
Solange Cailleaux Rodrigo A. B. Lopes-Martins Flávio Aimbire Renato S. B. Cordeiro E. Tibiriçá 《Naunyn-Schmiedeberg's archives of pharmacology》1999,359(6):505-511
The hypothesis that platelet-activating factor (PAF) plays a role in the modulation of the vasomotor tone and blood pressure
was put forward by our group in previous in vivo studies in anaesthetised rabbits. The present study was undertaken to investigate
the putative role of this lipid mediator in the vascular reactivity of the renal circulation, using the experimental model
of the isolated perfused rabbit kidney. Dose-response curves to noradrenaline-induced vasoconstriction were performed before
and after continuous infusions of two different PAF-receptor antagonists (WEB 2086 and yangambin) and of the phospholipase
A2 inhibitor mepacrine. The increases in renal perfusion pressure elicited by noradrenaline were potentiated by all the above-mentioned
treatments in a dose-dependent manner. Moreover, prostaglandin F2α-induced vasoconstriction was also potentiated by the administration of the PAF receptor antagonists and mepacrine. Furthermore,
the administration of PAF into the renal circulation induced dose-related and long-lasting vasodilator responses, which were
blocked by the PAF receptor antagonists. Nevertheless, PAF-induced renal vasodilation was also abolished by a pretreatment
with mepacrine or with the cyclooxygenase inhibitor indomethacin, suggesting that it enhances the secondary formation of vasodilator
arachidonic acid metabolites. The data indicate that PAF is involved in the modulation of the vasomotor tone in the renal
circulation, through the release of cyclooxygenase products, constituting an additional mechanism of modulation of smooth
muscle cell contractility to the ones exerted by well-known vasoactive substances of endothelial origin such as nitric oxide.
Received: 20 April 1998 / Accepted: 5 March 1999 相似文献
8.
9.
Oliver Gautschi Sacha I. Rothschild Qiyu Li Klazien Matter-Walstra Alfred Zippelius Daniel C. Betticher Martin Früh Rolf A. Stahel Richard Cathomas Daniel Rauch Miklos Pless Solange Peters Patrizia Froesch Thilo Zander Martina Schneider Christine Biaggi Nicolas Mach Adrian F. Ochsenbein 《Clinical lung cancer》2017,18(3):303-309
Background
Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non–small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone.Patients and Methods
We conducted a nonrandomized phase II trial with 2 sequential cohorts. In the first cohort, 77 patients were treated with 4 cycles of cisplatin, bevacizumab, and pemetrexed every 3 weeks, followed by bevacizumab plus pemetrexed maintenance until progression. In the second cohort, we treated 52 patients without bevacizumab, using maintenance with pemetrexed alone. Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), adverse events, and the treatment costs of the 2 cohorts were compared.Results
The median PFS from the time of registration was 6.9 months in cohort 1 and 5.6 months in cohort 2. The ORR was 62.3% in cohort 1% and 44.2% in cohort 2. The PFS (hazard ratio, 0.7; 95% confidence interval [CI], 0.5-1.0; P = .041) and ORR (odds ratio, 2.1; 95% CI, 1.0-4.3; P = .049) were better in cohort 1 than in cohort 2. No OS difference was found (hazard ratio, 1.0; 95% CI, 0.7-1.6; P = .890) after a median follow-up period of 47 months for cohort 1 and 27 months for cohort 2. The rate of grade ≥ 3 adverse events was greater in cohort 1. The treatment costs per patient were on average 1.4 times greater for cohort 1.Conclusion
The addition of bevacizumab increased the ORR and PFS, but not OS, in our nonrandomized trial. Furthermore, the addition of bevacizumab was associated with greater toxicity and higher costs. 相似文献10.
Oliver Gautschi Solange Peters Vincent Zoete Franziska Aebersold-Keller Klaus Strobel Bernhard Schwizer Astrid Hirschmann Olivier Michielin Joachim Diebold 《Lung cancer (Amsterdam, Netherlands)》2013
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug resistance. This information may help to develop effective targeted therapies for cancers with non-V600 BRAF mutations. 相似文献